Simon C. Pacey

Hills Road
Cambridge, ENG CB20QQ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Journal: Current oncology (Toronto, Ont.)

Published: April 05, 2026

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Journal: Investigational new drugs

Published: February 04, 2026

Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results.

Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 30, 2025

Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects.

Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: January 08, 2025

Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer.

Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 23, 2024

Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.

Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.

Journal: BJU international

Published: July 11, 2023

Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review.

Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review.

Journal: Cureus

Published: January 28, 2023

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study.

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study.

Journal: European urology open science

Published: January 18, 2022

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA.

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA.

Journal: Genome research

Published: May 03, 2021

Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?

Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?

Journal: BJU international

Published: March 28, 2021

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.

Journal: JTO clinical and research reports

Published: August 26, 2020

Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133+ cells in clear cell renal carcinoma.

Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133+ cells in clear cell renal carcinoma.

Journal: FASEB bioAdvances

Published: August 25, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026